MX347429B - Cristales de múltiples componentes que comprenden dasatinib y formadores de cocristales seleccionados. - Google Patents

Cristales de múltiples componentes que comprenden dasatinib y formadores de cocristales seleccionados.

Info

Publication number
MX347429B
MX347429B MX2014015433A MX2014015433A MX347429B MX 347429 B MX347429 B MX 347429B MX 2014015433 A MX2014015433 A MX 2014015433A MX 2014015433 A MX2014015433 A MX 2014015433A MX 347429 B MX347429 B MX 347429B
Authority
MX
Mexico
Prior art keywords
dasatinib
cocrystal formers
multicomponent crystals
multicomponent
gallate
Prior art date
Application number
MX2014015433A
Other languages
English (en)
Other versions
MX2014015433A (es
Inventor
Szelagiewicz Martin
Blatter Fritz
Chiodo Tiziana
Hafner Andreas
Hintermann Tobias
Salvador Beate
Siebenhaar Bernd
Vossen Marcus
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se filed Critical Basf Se
Publication of MX2014015433A publication Critical patent/MX2014015433A/es
Publication of MX347429B publication Critical patent/MX347429B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
    • C07C35/08—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings
    • C07C35/12—Menthol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C07C47/58—Vanillin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un sistema cristalino de componentes múltiples (co-cristal) que comprende un compuesto de la fórmula I (INN: Dasatinib) y un segundo compuesto seleccionado de metil-4-hidroxibenzoato, o nicotinamida, o galato de etilo, o galato de metilo, o galato de propilo, o etil maltol o vainillina, o mentol, o (1R,2S,5R)-(-), así como a un proceso para obtenerlo.
MX2014015433A 2012-06-15 2013-06-13 Cristales de múltiples componentes que comprenden dasatinib y formadores de cocristales seleccionados. MX347429B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659997P 2012-06-15 2012-06-15
EP12172172 2012-06-15
PCT/IB2013/054832 WO2013186726A2 (en) 2012-06-15 2013-06-13 Multicomponent crystals comprising dasatinib and selected cocrystal formers

Publications (2)

Publication Number Publication Date
MX2014015433A MX2014015433A (es) 2015-09-16
MX347429B true MX347429B (es) 2017-04-26

Family

ID=49758817

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015433A MX347429B (es) 2012-06-15 2013-06-13 Cristales de múltiples componentes que comprenden dasatinib y formadores de cocristales seleccionados.

Country Status (12)

Country Link
US (1) US9340536B2 (es)
EP (1) EP2861589B1 (es)
JP (1) JP6211072B2 (es)
KR (1) KR20150020683A (es)
CN (1) CN104379582A (es)
AU (1) AU2013276138B2 (es)
BR (1) BR112014031292A2 (es)
CA (1) CA2876539A1 (es)
ES (1) ES2637829T3 (es)
MX (1) MX347429B (es)
RU (1) RU2650524C2 (es)
WO (1) WO2013186726A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2637829T3 (es) 2012-06-15 2017-10-17 Basf Se Cristales multicomponentes que comprenden dasatinib y agentes de formación de cocristales seleccionados
CA2877030A1 (en) 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
EP2880019B1 (en) 2012-08-06 2016-07-13 Basf Se Multicomponent crystalline system comprising deferasirox and isonicotinamide and a process for the preparation thereof
MX2015004947A (es) 2012-10-19 2016-02-22 Basf Se Sistema cristalino multicomponente que comprende nilotinib y formadores de cocristal seleccionados.
EP3024830A2 (en) 2013-07-25 2016-06-01 Basf Se Salts of dasatinib in crystalline form
KR101831535B1 (ko) 2013-07-25 2018-02-22 바스프 에스이 무정형 형태의 다사티닙 염
US20180230140A1 (en) 2014-06-30 2018-08-16 Basf Se Multicomponent crystals of dasatinib with menthol or vanillin
IT201700006145A1 (it) 2017-01-20 2018-07-20 Cerbios Pharma Sa Co-cristallo di un composto antitumorale
IT201700006157A1 (it) * 2017-01-20 2018-07-20 Cerbios Pharma Sa Co-cristalli di un composto antitumorale
CA3069107A1 (en) * 2017-07-07 2019-01-10 Biocon Limited Polymorphic forms of dasatinib
JP7166754B2 (ja) 2017-11-22 2022-11-08 沢井製薬株式会社 ダサチニブ無水物含有製剤
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
TWI815137B (zh) 2018-06-15 2023-09-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽之結晶
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
CN112028896A (zh) * 2020-10-14 2020-12-04 奥锐特药业(天津)有限公司 阿卡替尼的新晶型及其制备方法
CN114805046B (zh) * 2022-04-25 2023-05-12 东华理工大学 香草醛与酰胺类化合物的共晶结构及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062778A1 (en) 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors
WO2004078163A2 (en) * 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
TWI338004B (en) * 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
SI1786799T1 (sl) * 2004-09-09 2012-12-31 Natco Pharma Limited Novi derivati fenilaminopirimidina kot inhibitorji BCR-ABL kinaze
CN101268072A (zh) * 2005-04-15 2008-09-17 库多斯药物有限公司 Dna-pk抑制剂
AR054438A1 (es) * 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
US20070105867A1 (en) 2005-09-21 2007-05-10 Bristol-Myers Squibb Company Oral administration of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
CN101370811A (zh) * 2005-11-10 2009-02-18 先灵公司 作为蛋白激酶抑制剂的咪唑并吡嗪化合物
AU2006315334B2 (en) * 2005-11-16 2011-05-19 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
WO2008079968A1 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
JP2010539156A (ja) 2007-10-23 2010-12-16 テバ ファーマシューティカル インダストリーズ リミティド ダサチニブ多形体およびその調製プロセス
CN104530052A (zh) * 2008-06-10 2015-04-22 普莱希科公司 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症
WO2010062715A2 (en) * 2008-11-03 2010-06-03 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010067374A2 (en) 2008-12-08 2010-06-17 Hetero Research Foundation Polymorphs of dasatinib
CZ20098A3 (cs) * 2009-01-13 2010-07-21 Zentiva, K.S. Lékové formy inhibitoru tyrosinových kináz
CA2757228C (en) * 2009-03-30 2018-01-02 Tibotec Pharmaceuticals Co-crystal of etravirine and nicotinamide
MX2012006375A (es) * 2009-12-03 2013-03-21 Astrazeneca Ab Co-cristales de un inhibidor de agregacion de plaquetas de triazolo [4, 5-d] pirimidina.
WO2012014149A1 (en) * 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited N-methylformamide solvate of dasatinib
WO2012069394A1 (en) 2010-11-22 2012-05-31 Basf Se Multicomponent system of rosuvastatin calcium salt and sorbitol
CN102030745B (zh) 2010-11-26 2012-05-09 江苏先声药物研究有限公司 Dasatinib溶剂合物及其制备方法
EP2699552A1 (en) 2011-04-18 2014-02-26 Basf Se Multicomponent crystalline system of rosuvastatin calcium salt and vanillin
CA2841655A1 (en) 2011-07-26 2013-01-31 Basf Se Multicomponent crystalline system of ezetimibe and proline
EP2788344A4 (en) 2011-12-06 2015-06-24 Basf Se MULTI-COMPONENT CRYSTALLINE SYSTEM OF VORICONAZOLE WITH FUMARIC ACID
US8796481B2 (en) 2011-12-30 2014-08-05 Basf Se Crystalline solvate and non-solvated forms of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′biphenyl]-2,2′-diyl]bis(oxy)]bis-dibenzo [d,f] [1,3,2]-dioxaphosphepine
BR112014016137B1 (pt) 2011-12-30 2021-02-09 Basf Se forma cristalina não solvatada, monossolvato de tolueno cristalino, solvato de acetona cristalino, composição, processo para a preparação do monossolvato de tolueno cristalino, processo para a preparação de uma forma cristalina não solvatada, processo para a preparação do solvato de acetona cristalino, método para obter o solvato de acetona cristalino, uso de uma forma cristalina, e, método para produzir um catalisador de metal de transição
BR112014024012A8 (pt) 2012-03-29 2017-07-25 Basf Se Cocristais, processo para a preparação dos cocristais, composição agroquímica, utilização da composição agroquímica e método para o controle da vegetação indesejável
US9328101B2 (en) 2012-05-25 2016-05-03 Basf Se Crystalline form B of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[B][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione
CA2871315C (en) 2012-05-25 2020-11-03 Basf Se Crystalline form a of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2h-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione
ES2637829T3 (es) 2012-06-15 2017-10-17 Basf Se Cristales multicomponentes que comprenden dasatinib y agentes de formación de cocristales seleccionados

Also Published As

Publication number Publication date
MX2014015433A (es) 2015-09-16
AU2013276138A1 (en) 2015-01-22
CN104379582A (zh) 2015-02-25
KR20150020683A (ko) 2015-02-26
RU2015100280A (ru) 2016-08-10
US20150133463A1 (en) 2015-05-14
BR112014031292A2 (pt) 2017-06-27
US9340536B2 (en) 2016-05-17
EP2861589B1 (en) 2017-05-17
AU2013276138B2 (en) 2017-02-23
ES2637829T3 (es) 2017-10-17
CA2876539A1 (en) 2013-12-19
WO2013186726A3 (en) 2014-02-20
EP2861589A4 (en) 2016-03-02
EP2861589A2 (en) 2015-04-22
JP2015525227A (ja) 2015-09-03
RU2650524C2 (ru) 2018-04-16
JP6211072B2 (ja) 2017-10-11
WO2013186726A2 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
MX2014015433A (es) Cristales de múltiples componentes que comprenden dasatinib y formadores de cocristales seleccionados.
AU2016204322A1 (en) N-arylamidine-substituted trifluoroethyl sulfide derivatives as acaricides and insecticides
CY1123670T1 (el) Κρυσταλλικο παραγωγο 6,7-ακορεστης-7-καρβαμοϋλ μορφινανης, και μεθοδος για την παραγωγη αυτου
EA201500173A1 (ru) Фунгицидные композиции
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
WO2015008218A3 (en) Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant
WO2013093931A3 (en) Novel prodrugs of phenolic drugs
FR2975990B1 (fr) Procede de preparation d'un compose organique fluore
WO2014017938A3 (en) Process for the synthesis of substituted urea compounds
WO2012131707A3 (en) Crystalline form of bortezomib, preparation method and pharmaceutical composition there f
WO2014159794A3 (en) Bicyclo [2.2.1] acid gpr120 modulators
TN2013000354A1 (en) Synthesis of 2-carboxamide cycloamino urea derivatives
NZ627473A (en) Aryloxyacetamide compound and pesticide
WO2014207567A3 (en) Process for the preparation of abiraterone and intermediates thereof
EP2883870B8 (en) Method for producing 1,4-benzoxazine compound
CY1114704T1 (el) Κρυσταλλικη μορφη δ του αλατος αργινινης της περινδοπριλης, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις οι οποιες την περιεχουν
IN2014MN00971A (es)
MX364529B (es) Nuevos ligandos del receptor de estrógeno.
PH12014501367A1 (en) Processes for making magnolol and derivatives thereof
WO2013072938A3 (en) Process for the preparation of roflumilast
WO2014195977A3 (en) Novel polymorphs of vismodegib
WO2014030173A3 (en) Improved process for preparation of atazanavir bisulfate
IN2013MU03508A (es)
WO2014167509A3 (en) Loxoprofen polymorphs and process for preparation of the same
MX2014012822A (es) Proceso para elaborar derivados de naftiridina.

Legal Events

Date Code Title Description
FG Grant or registration